The project
The Joint Action on Personalised Cancer Medicine (JA PCM) is a four-year European initiative aiming to support the implementation of personalised cancer prevention, diagnosis, treatment and follow-up strategies across Member States. Funded under the EU4Health Program, JA PCM brings together public health authorities, cancer centres, research organisations, and patient representatives from across Europe to reduce inequalities in access to innovation.
The project supports national health systems by:
- Coordinating seven pilot interventions across the cancer care continuum
- Developing practical tools, training programmes, and data infrastructure
- Promoting equity, ethical implementation, and long-term sustainability
- Aligning efforts with major EU frameworks such as Europe’s Beating Cancer Plan, the European Health Data Space, and UNCAN.eu

JA PCM is organised into 13 work packages, grouped under three thematic arms:
- Arm I – Personalised prevention and early detection
- Arm II – Personalised medicine
- Arm III – Personalised follow-up and tertiary prevention
Cross-cutting work packages address coordination, communication, training, ethics, and health technology assessment
Timeline
September 2025 – Project start
- Official kick-off meeting in Brussels
- Launch of internal platform, governance bodies, and communication tools

2026 – Pilot roll-out and baseline mapping
- Final deliverables and public reports
- Strategic roadmap for long-term national and EU-level actions
- Closing conference and knowledge transfer activities
2027 – Evaluation and data collection
- Mid-term analysis of pilot outcomes
- Development of guidelines and implementation toolkits
- Start of health technology assessment reports
2028 – Policy recommendations and sustainability planning
- Final deliverables and public reports
- Strategic roadmap for long-term national and EU-level actions
- Closing conference and knowledge transfer activities
August 2029 – End of project